Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy
- Substances:AnastrozoleCamizestrant+6
Greece- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:AstraZeneca AB
Rare diseases
Investigational molecules
Locations
Back to Greece182 clinical trials in Ioannina, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.
Greece
Greece
Greece
Greece
Greece
Greece
Greece
Greece
Greece
Greece
Greece
GreeceThe busiest research cities in the country
What the registry says about research in the country
Groundbreaking trials focusing on heart failure prevention and innovative treatments for cardiovascular diseases. Studies evaluating new combination therapies and investigating methods to reduce cardiovascular risks.
Multiple trials exploring the effectiveness of novel medications in reducing cardiovascular events and improving patient outcomes.
Innovative research targeting obesity and various forms of hypercholesterolemia. Studies include treatments for both adult and pediatric patients with metabolic conditions.
Clinical investigations focusing on new therapeutic approaches for managing metabolic disorders and their complications.
Advanced studies in asthma and pulmonary fibrosis treatment. Research evaluating new medications for improving lung function and managing severe respiratory conditions.
Trials examining innovative therapies for both acute and chronic respiratory conditions.
Research focusing on sickle cell disease and beta-thalassemia. Studies evaluating treatments for blood disorders and related complications.
Comprehensive trials investigating new therapeutic approaches for various blood disorders.
Studies investigating treatments for multiple sclerosis and stroke prevention. Research focused on improving neurological outcomes and disease management.
Trials evaluating innovative therapies for managing chronic neurological conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.